Low skeletal muscle mass is a predictive factor for chemotherapy dose-limiting toxicity in patients with locally advanced head and neck cancer

Article ID	Journal	Published Year	Pages	File Type
5642635	Oral Oncology	2017	8 Pages	PDF

Abstract

Low SMM is an independent risk factor for CDLT in LA-HNSCC patients treated with primary RCT. Pre-therapeutic estimation of SMM using routine CT-scans of the head and neck region may identify patients at risk of CDLT.

Keywords

LBM RCT HNSCC SMM CSA overall survival Computer-assisted image analysis Lean body mass Skeletal muscle mass Radiochemotherapy cross-sectional area Head and neck neoplasms Hounsfield units Head and neck squamous cell carcinoma Sarcopenia

Related Topics

Health Sciences Medicine and Dentistry Dentistry, Oral Surgery and Medicine

Preview

Low skeletal muscle mass is a predictive factor for chemotherapy dose-limiting toxicity in patients with locally advanced head and neck cancer

Authors

Anne W. Wendrich, Justin E. Swartz, Sandra I. Bril, Inge Wegner, Alexander de Graeff, Ernst J. Smid, Remco de Bree, Ajit J. Pothen,